Neuromodulation is the second-oldest and third-largest of Medtronic's business units. It was formed as we transferred our expertise in heart electrical stimulation to treat diseases and conditions involving the nervous system. Today, our products include neurostimulation systems and implantable drug delivery systems for chronic pain, severe spasticity, common movement disorders, psychiatric disorders, and urologic and gastrointestinal disorders.

Key Product Categories

Deep Brain Stimulation (DBS) Therapy*

Deep Brain Stimulation Therapy

DBS Therapy uses a surgically implanted neurostimulator, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas within the brain to block unwanted signals.
The DBS System includes:

  • a neurostimulator, which is typically implanted just under the skin of the upper chest;
  • a lead (thin set of wires) that carries the therapy signal to the electrodes, which deliver stimulation to the brain;
  • an extension (thin set of wires) that connects the lead to the neurostimulator.

Drug Infusion Systems*

Drug Infusion system to manage chronic pain

Drug infusion systems use two fully implantable components — a drug pump and an intraspinal catheter — to deliver precise amounts of medication directly into either the epidural or intrathecal spaces.

Because drug infusion systems deliver medication directly to the spinal cord, rather than traveling throughout the body like oral medications, intraspinal drug delivery may relieve symptoms with smaller amounts of medication than when taken orally. This may present an alternative for patients who do not respond to or experience side effects of therapeutic oral doses.

These systems are used to manage severe spasticity and chronic pain of malignant or non-malignant origin.

Conditions which may be treated with a drug infusion system**

Severe spasticity associated with:

Chronic pain of malignant or non-malignant origin:

**Chronic infusion of drugs or fluids tested as compatible and listed in the product labeling.

Gastric Stimulation Systems*

Neurostimulator Device Controls Chronic Nausea

A small medical device called a neurostimulator is implanted under the skin, usually in the lower abdominal region. Two insulated wires called leads are implanted in the stomach wall muscle and then connected to the neurostimulator, which sends electrical pulses through the leads to stimulate the smooth muscles of the lower stomach. This may help to control the chronic nausea and vomiting caused by gastroparesis.


Sacral Neuromodulation Systems*

Sacral Neuromodulation System located near tailbone

These devices, which are typically implanted in the upper buttock, send mild electrical pulses to the sacral nerves, located near the tailbone. The sacral nerves control the bladder, the lower bowels and the genital organs, and play a major role in the control of urinary and bowel function.


Intractable functional lower pelvic tract dysfunction, including:

For Patients
See our Bladder Control and Bowel Control websites.

Spinal Cord Stimulation Systems*

Spinal Cord Stimulation device for chronic pain management

Spinal cord stimulation (a type of neurostimulation therapy) is delivered with a small spinal cord stimulator implanted. It delivers mild electrical impulses to a patient's spine to interrupt the pain message. Instead of feeling pain, most patients feel a tingling sensation called parasthesia.

Patients can adjust the strength and location of stimulation using a handheld programmer. For example, patients can regulate different levels of stimulation at different times of the day or for various activities – such as walking, sleeping, or sitting. Depending on the neurostimulation system, the device may be able to automatically adjust stimulation when a patient changes position.

* The indication for the treatment of these conditions using Spinal Cord Stimulation is limited to the trunk and/or limbs.

For Patients
See our Tame the Pain website.

 *For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use.

Last updated: 10 Jun 2014

Section Navigation

Additional information


South Africa